Get started
Author

Justin Nedzesky

A genetically engineered Fc-binding amphiphilic polypeptide for congregating antibodies in vivo
2019 · Wen Liu, Stephanie Wong-Noonan, et al. · Acta Biomaterialia · 21
Analysis of Peer Review in a Student-Run Scientific Journal
2022 · Justin Nedzesky, Meredith Bennett, et al. · Double Helix A Journal of Critical Thinking and Writing · 9
PDF
Clinical manifestations, healthcare resource utilization, and costs among patients with long-chain fatty acid oxidation disorders: a retrospective claims database analysis
2024 · Erru (Christy) Yang, Zhenzhen Fang, et al. · Current Medical Research and Opinion · 4
PDF
Glycogen Storage Disease Type Ia: A Retrospective Claims Analysis of Complications, Resource Utilization, and Cost of Care
2025 · Eliza Kruger, Justin Nedzesky, et al. · Journal of health economics and outcomes research · 3
Glycogen Storage Disease Type Ia: A Retrospective Claims Analysis of Complications, Resource Utilization, and Cost of Care
2025 · Eliza Kruger, Justin Nedzesky, et al. · Journal of health economics and outcomes research · 2
PDF
Real-world Persistence in Patients with Tardive Dyskinesia: A Comparative Study of Valbenazine and Deutetrabenazine XR (P7-16.005)
2026 · Riddhi Doshi, Shivani Pandya, et al. · Neurology
Identification of Functional Impairment in Individuals with Huntington’s Disease Chorea: A Modified Delphi Consensus Study (P2-16.011)
2026 · Olga Klepitskaya, Lauren Seeberger, et al. · Neurology
Pcr90 Valbenazine Improves Physical, Social, and Emotional Impacts on the Tardive Dyskinesia Impact Scale (tdis): Post Hoc Analyses of Kinect-pro™ Data
2026 · Eduardo Dunayevich, M. Mercedes Perez-Rodriguez, et al. · Value in Health
HSD80 Assessing Real-World Dosing Patterns for Vesicular Monoamine Transporter-2 Inhibitors (VMAT2i), Valbenazine and Deutetrabenazine, Among Patients with Tardive Dyskinesia (TD) in a Nationwide US Claims Database
2025 · M. Mercedes Perez-Rodriguez, Justin Nedzesky, et al. · Value in Health
PCR191 Impact Of Valbenazine On Improvements In Health-Related Quality of Life (HRQoL) In Patients With Tardive Dyskinesia (TD): EQ-5D-5L Results From A Phase 4 Randomized Withdrawal Study (NCT03891862)
2025 · Michael Serbin, Justin Nedzesky, et al. · Value in Health
PCR190 Impact of Valbenazine on Improvements in Disability and Functional Impairment in Patients With Tardive Dyskinesia (TD): Sheehan Disability Scale (SDS) Results From a Phase 4 Randomized Withdrawal Study (NCT03891862)
2025 · Michael Serbin, Justin Nedzesky, et al. · Value in Health
HSD59 Disparities in Tardive Dyskinesia Diagnosis and Treatment Among the US Medicare Population
2025 · Yvonne Yang, Justin Nedzesky, et al. · Value in Health
P18 Disparities in Antipsychotic Prescribing Among the US Medicare Population
2025 · Yvonne Yang, Justin Nedzesky, et al. · Value in Health
Improvement in Quality of Life and Functional Status Following Valbenazine Treatment in Patients with Tardive Dyskinesia: Real-world Data from a Chart Extraction and Clinician Survey (P10-5.019)
2025 · Rimal Bera, Justin Nedzesky, et al. · Neurology
RET testing and treatment patterns among patients with aNSCLC in US clinical practice.
2023 · Eunice Kim, Jesse Sussell, et al. · Journal of Clinical Oncology
Works count: 16
Citation count: 39
H-index: 3
I10-index: 1
Year
Topic
Type